FDA Review Paused Due to Application Deficiencies, But Approval Not Yet Rejected
Aquestive Therapeutics (NASDAQ:AQST) has hit a regulatory hurdle after the FDA identified deficiencies in its New Drug Application (NDA) for Anaphylm, its investigational sublingual film for treating severe allergic reactions. The FDA's notice has paused any immediate discussions about labeling and post-marketing commitments. However, the review for Anaphylm is still ongoing, and no final decision has been made. Importantly, specifics about the deficiencies have not been disclosed, and Aquestive is actively working to resolve them before the scheduled PDUFA action date of January 31, 2026.
Global Regulatory Plans Continue as U.S. Timeline Faces Uncertainty
Despite this regulatory setback in the United States, Aquestive is aggressively expanding globally. The company continues to develop regulatory filings for Anaphylm in Canada, Europe, and the United Kingdom, with positive early feedback from the European Medicines Agency that no additional clinical trials are needed before submission. Aquestive plans to file with Health Canada in the first half of 2026 and in Europe during the second half, while feedback from UK authorities is expected in early 2026.
Key Regulatory Milestones for Anaphylm
| Region | Current Status | Next Step | Estimated Timing |
|---|---|---|---|
| United States (FDA) | Deficiencies Identified – Review Ongoing | Address Deficiencies, Await FDA Feedback | PDUFA Date: Jan. 31, 2026 |
| Canada (Health Canada) | Regulatory Engagement Initiated | New Drug Submission | First Half 2026 |
| Europe (EMA) | Positive Initial Feedback | Marketing Authorization Application | Second Half 2026 |
| United Kingdom (MHRA) | Initial Review in Progress | Awaiting Regulatory Feedback | First Quarter 2026 |
Clinical Data Supports Potential First-in-Class Oral Epinephrine
Anaphylm has undergone a substantial clinical development program, including 11 independent studies with nearly 967 total administrations across 411 subjects. Results demonstrated a pharmacokinetic profile comparable to existing epinephrine auto-injectors, and the product was generally well tolerated. Aquestive even conducted a unique oral allergy syndrome (OAS) study, highlighted for its real-world relevance.
Financial Position Strengthens Expansion Plans
Aquestive ended 2025 with approximately $120 million in cash and cash equivalents—providing what the company believes is sufficient funding to complete the U.S. regulatory process (if approved) and to pursue global expansion. Hiring for its U.S. sales force is on hold until FDA approval is secured.
| Key Metric | Value (as of Dec. 31, 2025) |
|---|---|
| Cash & Equivalents | $120 million |
| Clinical Subjects Exposed | 411 |
| Total Administrations | 967 |
| Single/Repeat Doses | 840 / 127 |
What’s Next? Key Takeaways for Investors and Stakeholders
The current regulatory uncertainty in the U.S. raises the risk of potential delays for Anaphylm’s approval, especially if additional FDA feedback is slow to materialize. However, the foundation for global regulatory progress and a sizeable clinical data set offer multiple paths to commercialize this first-of-its-kind oral epinephrine film.
Aquestive’s strong cash position underpins their continued confidence and ability to advance Anaphylm in the U.S. and internationally. The next few months will be critical as the company seeks clarity from the FDA and pursues parallel regulatory initiatives abroad.
For now, stakeholders will be keenly awaiting further updates on both U.S. regulatory developments and the international submission calendar—with the potential for Anaphylm to reshape severe allergy management if ultimately approved.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI